Integrated Assessment of Predicted MHC binding and Cross-conservation with Self Reveals Patterns of Viral Camouflage by He, Lu et al.
University of Rhode Island
DigitalCommons@URI
Institute for Immunology and Informatics Faculty
Publications Institute for Immunology and Informatics (iCubed)
2014
Integrated Assessment of Predicted MHC binding
and Cross-conservation with Self Reveals Patterns
of Viral Camouflage
Lu He
Anne S. DeGroot
URI, dr.annie.degroot@gmail.com
See next page for additional authors
Creative Commons License
This work is licensed under a Creative Commons Attribution 3.0 License.
Follow this and additional works at: https://digitalcommons.uri.edu/immunology_facpubs
Terms of Use
All rights reserved under copyright.
This Article is brought to you for free and open access by the Institute for Immunology and Informatics (iCubed) at DigitalCommons@URI. It has
been accepted for inclusion in Institute for Immunology and Informatics Faculty Publications by an authorized administrator of
DigitalCommons@URI. For more information, please contact digitalcommons@etal.uri.edu.
Citation/Publisher Attribution
He et al.: Integrated assessment of predicted MHC binding and cross-conservation with self reveals patterns of viral camouflage. BMC
Bioinformatics 2014, 15(Suppl 4):S1.
Available at: http://dx.doi.org/10.1186/1471-2105-15-S4-S1
Authors
Lu He, Anne S. DeGroot, Andres H. Gutierrez, William D. Martin, Lenny Moise, and Chris Bailey-Kellogg
This article is available at DigitalCommons@URI: https://digitalcommons.uri.edu/immunology_facpubs/11
RESEARCH Open Access
Integrated assessment of predicted MHC binding
and cross-conservation with self reveals patterns
of viral camouflage
Lu He1, Anne S De Groot2,3, Andres H Gutierrez2, William D Martin3, Lenny Moise2,3, Chris Bailey-Kellogg1*
From The 3rd ISV Pre-conference Computational Vaccinology Workshop (ICoVax 2013)
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Abstract
Background: Immune recognition of foreign proteins by T cells hinges on the formation of a ternary complex
sandwiching a constituent peptide of the protein between a major histocompatibility complex (MHC) molecule
and a T cell receptor (TCR). Viruses have evolved means of “camouflaging” themselves, avoiding immune
recognition by reducing the MHC and/or TCR binding of their constituent peptides. Computer-driven T cell
epitope mapping tools have been used to evaluate the degree to which particular viruses have used this means of
avoiding immune response, but most such analyses focus on MHC-facing ‘agretopes’. Here we set out a new
means of evaluating the TCR faces of viral peptides in addition to their agretopes, integrating evaluations of both
sides of the ternary complex in a single analysis.
Methods: This paper develops what we call the Janus Immunogenicity Score (JIS), bringing together a well-
established method for predicting MHC binding, with a novel assessment of the potential for TCR binding based
on similarity with self. Intuitively, both good MHC binding and poor self-similarity are required for high
immunogenicity (i.e., a robust T effector response).
Results: Focusing on the class II antigen-processing pathway, we show that the JIS of T effector epitopes and null
or regulatory epitopes deposited in a large database of epitopes (Immune Epitope Database) are significantly
different. We then show that different types of viruses display significantly different patterns of scores over their
constituent peptides, with viruses causing chronic infection (Epstein-Barr and cytomegalovirus) strongly shifted to
lower scores relative to those causing acute infection (Ebola and Marburg). Similarly we find distinct patterns
among influenza proteins in H1N1 (a strain against which human populations rapidly developed immunity) and
H5N1 and H7N9 (highly pathogenic avian flu strains, with significantly greater case mortality rates).
Conclusion: The Janus Immunogenicity Score, which integrates MHC binding and TCR cross-reactivity, provides a
new tool for studying immunogenicity of pathogens and may improve the selection and optimization of antigenic
elements for vaccine design.
Background
Cellular immune defenses against infectious diseases are
dependent on the immune system’s ability to identify and
control invading pathogens without causing too much
collateral damage. To accomplish that, the immune sys-
tem employs complex networks of interacting cells and
molecules. In one key network, Antigen Presenting Cells
(APCs) process and then present to circulating T cells
peptides that they have derived from pathogenic proteins.
An APC loads such a peptide, called a T cell epitope,
onto its Class II Human Leukocyte Antigen (HLA), also
known as Major Histocompatibility Complex (MHC).
Engagement of the T Cell Receptor (TCR) with the T cell
epitope:MHC II complex on the surface of the APC trig-
gers a cascade of events leading to activation of the T cell
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response. Thus the ternary MHC:T-cell epitope:
TCR complex connects the APC to the responder T cell
[1,2] (Figure 1).
This antigen-presenting pathway is constantly proces-
sing proteins that have been sampled from the extracellu-
lar environment. In the case of viruses and bacteria,
peptides (derived from their constituent proteins) that
bind MHC and TCR are recognized as foreign and trigger
an immune response. T helper (MHC class II-restricted)
epitopes within viral and bacterial proteins are a necessary
component of immune protection against these pathogens
since the presentation of a T-cell epitope in the context of
MHC Class II molecules is essential for a B-cell to be sti-
mulated and produce high-affinity and high-titer antibo-
dies. Since this interaction is the one that initiates a
specific immune response against the pathogen, one
means by which pathogens evade immune response is to
present proteins with lower immunogenic potential [3].
(Similar pressure results from the class I pathway wherein
CD8+ cytotoxic T lymphocytes recognize and destroy
infected cells, but this paper focuses on class II.)
The recognition of a peptide depends on both the MHC
face and the TCR face (Figure 1), giving a pathogen two
different routes for escape by modification of its immuno-
genic peptides. In order to assess immunogenic potential
and study escape on a genomic scale, it is necessary to
apply computational tools. On the MHC-binding side, a
number of algorithms have been developed and used
to map T cell epitopes (both MHC Class I and Class
II-restricted) within protein molecules of various origins
(see review and a current list of immunoinformatics tools
in reference [4]). Many algorithms rely on the linear nat-
ure of T cell epitopes as it simplifies modeling their inter-
actions with MHC in defined binding pockets, which
contrasts with the complexities of B cell epitope prediction
that involves the interaction of discontinuous antigen
sequences with highly variable complementarity determin-
ing regions of antibodies. Such in silico predictions of
Figure 1 The two-faced T cell epitope. The ternary MHC: peptide epitope: TCR complex drives the class II immune response (structure from pdb id
1fyt; rendered with PyMol (Schrödinger, LLC)). Some of the epitope side-chains (blue, spacefill) interact with the MHC (green, cartoon), while others
interact with the TCR (orange, cartoon). A TCR may recognize many peptides that have similar TCR-facing sequences but different MHC-facing
sequences, as long as the peptide still binds the same MHC. We develop an integrated scoring mechanism that accounts for both aspects of immune
recognition, combining the EpiMatrix epitope predictor (to identify peptides that are good MHC binders) with an assessment of cross-reactivity with
human genome (to identify peptides that are unlike self and thus more likely to be recognized by TCR from effector T cells).
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T-helper epitopes have been successfully applied to the
design of vaccines [5,6] and to the selection of epitopes in
studies of autoimmunity [7]. We use here the EpiMatrix
system, a suite of epitope mapping tools that has been vali-
dated over the course of more than a decade, both in vitro
and in vivo (for example, see references [8-14]).
Computational T-cell epitope mapping tools have
been used to evaluate the degree to which selected
pathogens have reduced their epitope content in order
to evade immune response. For example, one study of
CD8+ T cell epitopes in viruses showed that those
infecting humans contained fewer CD8+ T-cell epitopes
than non-human-host viruses, with human-host viral
proteins expressed earlier in the life cycle having a
lower epitope density than those expressed later [15].
Similarly, a study of CD8+ T-cell epitopes in bacteria
demonstrated that host cytosol-exposed proteins showed
clear escape mutations and low epitope density while
proteins not translocated to the cytosol showed no
escape mutations and some of them were found to have
high epitope density [16]. We have also previously per-
formed large-scale analyses of human proteins to deter-
mine whether the number of T-cell epitopes in secreted
or extracellular proteins is reduced in comparison with
other non-secreted proteins [17], and found evidence
supporting our hypothesis that highly prevalent secreted
proteins that are present in the serum are ‘naturally
deimmunized’ with respect to other, less prevalent and
more internal proteins.
Characterizing and making predictions for the TCR
side of recognition is substantially harder than for the
MHC side, due to the essentially unpredictable variabil-
ity in the complementarity determining regions of the
TCR. However, in the context of pathogenic immune
escape, there is one critical aspect that is more tractable
for analysis: similarity to self. Autologous proteins are
also processed and presented by antigen presenting
cells, but they do not usually trigger immune responses
by T cells due to mechanisms of central and peripheral
tolerance. For T cells, initial self/non-self discrimination
occurs in the thymus during neonatal development
when medullary epithelial cells express tissue-specific
self-proteins and present the epitopes therein to imma-
ture T cells. T cells recognizing self-antigens with high
affinity are deleted; auto-reactive T cells with moderate
affinity may escape deletion and be converted to func-
tion as ‘natural’ regulatory T cells (Treg) cells [18].
While central deletion of auto-reactive T cells is the pri-
mary means by which tolerance is established, some
auto-reactive T cells escape this mechanism, potentially
contributing to autoimmunity. Natural regulatory T cells
that recognize epitopes from autologous proteins circu-
late in the periphery, suppressing anti-self immune
response. Both thymic-derived (natural or nTreg) and
induced (iTreg) regulatory T cells bearing T cell recep-
tors that recognize self-antigens are involved in regulat-
ing autoimmunity [19].
Assuming then that autologous proteins are less likely
to generate T effector responses, an immune escape
mechanism for a pathogen is to ensure that MHC-bind-
ing peptides within its proteins present human-like TCR
faces. This is a more relaxed requirement than full
“humanization” (ensuring that the pathogenic and
human peptide are identical); instead, the peptides only
need to be cross-reactive (binding the same TCRs).
Cross-reactivity is an intrinsic characteristic of the T cell
receptor, in that each TCR can potentially interact with
many different T cell epitopes [20-22]. T cell epitope
cross-reactivity is also critical to many aspects of T cell
biology, including positive and negative T cell selection
in the neonatal thymus [23,24].
Thus one means of immune escape by viruses may be to
present T cell epitopes recognized by nTregs or iTregs.
TCR-level cross-reactivity with autologous proteins is of
great interest in general as T cells responding to a foreign
protein may have diminished or altered type of immune
response, and auto-reactive T cells may be triggered by
this cross-reactivity [25]. We are particularly interested in
understanding to what extent cross-reactivity might differ
between commensal viruses (e.g., Epstein-Barr and cyto-
megalovirus) that can continuously infect humans for
years while demonstrating very limited pathology
("hit-and-stay” viruses, as described by Hilleman [3]), as
opposed to other ("hit-and-run”) viruses that are known to
cause significant immunopathology and death (e.g., Ebola
and Marburg). We also wish to determine whether T cell
epitopes from any viral source might be less likely to trig-
ger an immune response when tested in humans, if cross-
reactivity with self was found to be present.
Computational analyses of sequence similarity between
predicted epitopes in pathogens and in the human genome
have been used to study TCR-level cross-reactivity.
Previous studies [26] showed for class I epitopes that the
recognition of a peptide-MHC by the T-cell receptor is
flexible, and as a result, about one-third of non-self
peptides are expected to be indistinguishable (by T-cells)
from autologous peptides. T-cells are expected to remain
tolerant to self, leading to the creation of “holes” in the
immune recognition repertoire for cross-reactive foreign
epitopes. The overlap with self increases the need for effi-
cient self-tolerance, as many self-similar non-self peptides
could initiate an autoimmune response.
So as to enable broad computational studies of cross-
reactivity, we recently developed a new immunoinformatic
tool, JanusMatrix [27]. This tool, enabled by the EpiMatrix
T cell epitope-mapping platform described above, is
designed to easily and efficiently identify potential cross-
reactivity among T cell epitopes computationally mapped
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for human pathogens, the human genome, and the human
microbiome. An initial evaluation of validated Treg epi-
topes showed that their TCR-facing residues had statisti-
cally greater TCR cross-reactivity with human sequences.
Teff epitope and Treg epitope cross-reactivities with
human sequences were also different from random nine-
mers. We postulated that some of the overlap between
human pathogens and the human genome might be due
to co-opting of human-genome cross-reactivity by human
pathogens to escape immune response.
Building on this observation, this paper presents a new
framework for quantitatively characterizing immunogeni-
city risk, unifying the MHC and TCR sides of immune
recognition. The Janus Immunogenicity Score (JIS) pro-
vides a probabilistic assessment of the potential of a pep-
tide to induce a T effector response, combining evaluation
of MHC binding potential with identification of cross-
reactivity against the human genome. We show that JIS is
predictive of Teff data deposited in the immune epitope
database (IEDB). We then show that it reveals patterns of
camouflage that differ between hit-and-stay viruses that
cause chronic infection (Epstein-Barr and cytomegalo-
virus) and hit-and-run ones that cause acute infection
(Ebola, Marbug, and plant-host viruses). We also consider
a wide range of other human-host viruses and see that
most appear quite similar in terms of their relative camou-
flage, while some are striking outliers. We finally zoom in
and apply a similar analysis to specific influenza proteins
from different strains, characterizing their relative visibility
to the human immune system.
Methods
Janus immunogenicity score
The Janus immunogenicity score J(p; A) is defined for a
peptide p with respect to a set A of MHC alleles. Through-
out this manuscript, we use for A eight common represen-
tative alleles (DRB1*0101, 0301, 0401, 0701, 0801, 1101,
1301, 1501) that “cover” the genetic backgrounds of most
humans worldwide [28]. The analysis is performed by
breaking peptide p into a set of overlapping 9mers, and
assessing each such 9mer e for both MHC binding to each
allele a A, FMHC(e;a), and also conditional TCR recogni-
tion of the epitope: MHC complex, FTCR|MHC(e;a) if e is
an MHC binder. Then J(p; A) combines information
across alleles and epitopes.
MHC binding: FMHC(e;a)
EpiMatrix is a pattern-matching algorithm used for identi-
fication and prediction of T cell epitopes [29]. EpiMatrix
evaluates binding potential of every 9mer in a protein
sequence to the eight common class II HLA alleles listed
above. EpiMatrix raw scores are normalized to Z-scores.
Peptides with Z scores above 1.64 comprise the top 5%,
and it is these peptides that are defined as “hits” and
considered potentially immunogenic.
For an epitope e that is predicted to bind allele a (i.e.,
meeting the threshold), FMHC(e;a) is defined as the cumu-
lative value in the Normal distribution for the Z-score
(Figure 2, left) - a higher Z-score indicates a higher prob-
ability to be immunogenic. For a predicted non-binder
against allele a, FMHC(e;a) is undefined. Except for one
illustrative discussion point, the 5% threshold is used
throughout the results.
TCR recognition conditioned on MHC binding: FTCR|MHC(e;a)
JanusMatrix [27] examines T cell epitopes, predicted by
EpiMatrix, identifying as potentially cross-reactive those
that are predicted to bind the same MHC (though per-
haps with different amino acid composition on the
MHC-facing side) while presenting the same amino acids
to the TCR. JanusMatrix searches for such potentially
cross-reactive TCR-facing epitopes across different
sequence databases.
Here the extent of epitope cross-reactivity is assessed
against the human genome (UniProt reviewed [30]). Note
that the evaluation is conditional; only predicted MHC bin-
ders are considered. An empirical distribution is employed
to calibrate the expected number of cross-reactive hits and
convert the observed number into a probabilistic score. In
particular, a 1,000,000 residue pseudoprotein, randomly
generated at a natural amino acid frequency composition
[31], was broken into overlapping 9mers and assessed for
predicted epitopes binding to one or more alleles and for
human genome cross-reactivity of those epitopes. FTCR|
MHC(e;a) is then the tail probability in this empirical distri-
bution (Figure 2, right) - fewer cross-reactive hits implies a
higher probability of being immunogenic.
Integrated Janus Immunogenicity Score: J(p; A)
Let E be the set of 9mer epitopes within p that are pre-
dicted to bind one or more alleles. Each such epitope e is
evaluated against each allele a in A. A joint probability of
MHC binding and conditional TCR binding ensures that
both sides of the epitope sandwich are satisfied - the com-
bination of good MHC and good TCR binding implies a
higher probability of being immunogenic. A joint probabil-
ity over the alleles A encodes the notion that a promiscu-
ous epitope is more likely to be immunogenic [32]. Alleles
are assumed to be independent, from a distinct, represen-
tative set, so the joint probability is simply the product of
the probabilities; to avoid numerical problems with small
numbers, sums of log probabilities are employed in prac-
tice. Since the scores are only defined for epitopes, a uni-
form penalty term is incorporated as the contribution (in
place of the log joint probability) for the alleles for which
an epitope is a non-binder. The results presented use log
0.5 as this penalty, though the same trends were observed
with other choices. The average is taken over all the epi-
topes (predicted binders) in the peptide, treating each
independently (assuming they are presented separately)
and uniformly (though an assessment of processing
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probability could readily be incorporated). In summary,
the Janus immunogenicity score J is computed as:
J
(
p;A
)
=
1
|E|
∑
e∈E
∑
a∈A
log
(
FMHC (e; a) · FTCR|MHC (e; a)
)
Teff phenotype data
T cell data (ELISA, ELISPOT, and ICS) for five relevant
cytokines (IFNg, IL-4, IL-17, TGFb, and IL-10) MHC-
typed to one of the eight representative alleles listed
above was downloaded from the IEDB [33]. A peptide
was classified Teff-pos if any of the cytokines IFNg,
IL-4, or IL-17 was reported with a Positive measurement
and neither of the cytokines TGFb and IL-10 was; else it
was classified Teff-neg/null.
Viruses
To study the two extremes of viral camouflage, four
viruses from the UniProt reviewed set were selected:
Epstein-Barr virus (EBV; strain AG876) and cytomegalo-
virus (CMV; strain Merlin) were selected to serves as
representatives of long-lived infection viruses, and Ebola
(strain Mayinga-76) and Marburg (strain Musoke-80)
were selected to serve as representatives of short-lived/
zoonotic viruses. The JIS for each overlapping 15mer
“fragment” was computed for each virus; 15mer fragments
with no predicted epitopes were separately noted. As a
control for the zoonotic extreme, a set of 73 plant-host
viruses from [34] was likewise processed, with the entire
set of fragments collected in aggregate.
For a more diverse set of human-host viruses, the all-
fragment analysis was performed on all 51 human-host
viruses [34]. Each virus was characterized by the median
JIS in the distribution over all its fragments, treating
non-epitopes as the lowest value in the distribution.
Flu proteins
To study differences among related strains of the same
virus, JIS was computed for each 15mer fragment in three
representative influenza A strains: H1N1 (A/California/07/
2009), the most recent pandemic strain; H5N1 (A/Goose/
Guangdong/1/1996 H5N1 genotype Gs/Gd), a representa-
tive H5 avian influenza strain that has been responsible for
many human deaths; and H7N9 (A/Shanghai/2/2013),
also a recently emerged avian strain that caused more
than 100 infections and 44 deaths in 2013. The JIS distri-
bution was evaluated separately for the fragments in each
of the two surface proteins hemagglutinin (HA) and
neuraminidase (NA), as well other common proteins:
nucleoprotein (NP), matrix proteins (M1 and M2), and
non-structural proteins (NS1 and NEP).
Results and discussion
Teff phenotype characterization
A total of 588 peptides with Teff-pos peptide responses
and 76 with Teff-neg/null responses were identified from
the IEDB. To assess whether JIS is characteristically differ-
ent for Teff-pos and Teff-neg/null, the distributions
of scores for each set were separately characterized.
The epitope predictor threshold separating MHC binders
Figure 2 Components of the Janus Immunogenicity Score. JIS combines a prediction of MHC binding with a prediction of TCR binding
conditioned on MHC binding. (left) MHC binding is predicted by EpiMatrix, which makes an allele-specific assessment of binding relative to a
Normal distribution. The JIS contribution is the cumulative probability for those peptides exceeding a given threshold. (right) MHC-conditioned
TCR binding is analyzed by JanusMatrix, which makes an allele-specific assessment of how many peptides in the human genome are predicted
to bind the same MHC (possibly with different amino acids in the MHC pockets) and present the same amino acids to the TCR. The JIS
contribution is the tail probability with respect to this empirical distribution. The plot is truncated at 10.
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vs. non-binders is typically set to control the false positive
rate (by taking only the most confident predictions), but it
also naturally impacts the false negative rate. In this data-
set, the standard 5% threshold eliminated 11% of the Teff-
pos peptides and 20% of the Teff-neg/null peptides as hav-
ing no predicted epitopes, while a more relaxed 10%
threshold eliminated 4% and 5%, respectively. While these
data points could be considered false negatives for immu-
noinformatics analysis, they might also be false positives in
the T cell assay. To be consistent with standard practice
and keep false positive rate low, the 5% threshold was
employed for the remainder of the analysis.
Figure 3 illustrates the fraction of non-binders and the
JIS distributions for the Teff-pos and Teff-neg/null pep-
tides. The Wilcoxon rank-sum test indicates that the Teff-
neg/null distribution is “less than” the Teff-pos one (i.e.
predicted to be less immunogenic overall), with a p-value
of .0002 when including non-binders in the test, giving
them an arbitrary lowest score, and .002 when testing just
the binders. Thus we conclude that JIS does indeed distin-
guish immunogenicity risk, separating T cell epitopes that
induce regulatory cytokines or no detected immune
response from those that are associated with T effector
cytokines, for this dataset.
While JIS is computed over the eight standard alleles
(capturing increased likelihood of immunogenicity for
promiscuous binders), most peptides in the IEDB were
tested for only one allele. The dataset includes 646 allele-
specific characterizations for the 588 Teff-pos peptides
and 79 for the 76 Teff-neg/null ones. Computing JIS for
just the tested allele (ignoring the fact that other alleles, if
tested, might be consistent) results in the distributions
illustrated in Figure 4. There is no longer a distinction
between Teff-pos vs. Teff-neg/null non-binders, and thus
the Wilcoxon p-value for the entire set increases to .06.
However, the distributions of the binders are still signifi-
cantly different, at a p-value of .008, and there is a striking
peak in the distribution at around 0 (i.e., a log-probability
of 1) for Teff-pos peptides. Thus even in this weaker test
(throwing away valuable predictive features due to sparse
testing), we conclude that JIS is highly informative regard-
ing immunogenicity, revealing a clear difference between
pathogen-derived peptides that are reported as being asso-
ciated with effector cytokines and those that are reported
to be associated with Treg or null (absent) immune
responses.
Chronic vs. acute viruses
As Figure 5 illustrates, there are strong differences in the
JIS distributions for the 15mer fragments in hit-and-stay
viruses vs. those in the hit-and-run ones. EBV and CMV
are predicted to have a relatively larger percentage of
Figure 3 JIS of IEDB peptides determined to be Teff-pos vs. those determined to be Teff-neg/null. (left) Percentage of peptides that are
predicted non-binders for all alleles; (right) JIS distributions (smoothed by kernel density estimation) of peptides predicted to bind at least one
allele, truncated at a minimum of -8.
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Figure 4 JIS of IEDB peptides determined to be Teff-pos vs. those determined to be Teff-neg/null with JIS using only the allele tested
in the experiment. (left) Percentage of peptides that are predicted non-binders for the tested allele; (right) JIS distributions (kernel density
estimation) of peptides predicted to bind the tested allele.
Figure 5 JIS of 15mer fragments for representative viruses of different infection types. (left) Percentage of fragments predicted to be
non-binders; (right) JIS distributions (kernel density estimation, truncated at -7) of predicted binders; differences in total areas are due to
different percentages of non-binders.
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non-binder fragments and less immunogenicity for the
binder fragments, while Ebola and Marbug (lines sub-
stantially overlapping in the mode of the distribution) are
predicted to have more immunogenic fragments. Plant-
host viruses (which do not infect humans) were used as a
control, since these viruses can be assumed not to have
any significant evolutionary contact with the human
immune system. This set of viruses has a lower percentage
of binders than Marburg, but higher JIS. Wilcoxon rank-
sum tests, again treating non-binders as the lowest score,
support the observed order EBV < CMV < Ebola =
Marburg < plant-host viruses, with p-values approximately
0 for EBV vs. others and CMV vs. others, 2*10-6 for Ebola
vs. plant-host viruses, and 6*10-4 for Marburg vs. plant-
host viruses. Most of these relationships hold even among
just the binders, indicating a significant shift in the quanti-
tative scores, though the EBV vs. CMV p-value increases
to .03 and EBV vs. Marburg to .01; CMV vs. Marburg
crosses the usual line up to .06. Thus we conclude that the
immunogenicity profiles of commensal hit-and-stay
viruses are significantly different from hit-and-run viruses
that cause acute disease and high mortality, in two ways.
Commensal viruses appear to avoid immune response by
(1) reducing their epitope content and (2) adopting more
human-like TCR faces among the remaining epitopes,
when compared to acute viruses and plant-virus controls.
Broad set of human-host viruses
Figure 6 plots the median JIS among the fragments for
each virus, with the chronic vs. acute case study viruses
plotted at the bottom and the broad set stacked up
above them (at arbitrary y coordinates to avoid overlap).
Most of those on the low JIS side (various herpesviruses
including a different EBV; astrovirus; heptatitis C virus)
do indeed chronically infect humans and thus face evo-
lutionary pressure to camouflage themselves reducing
immune response. Figure 7 details the non-binder frac-
tions and JIS distributions of the viruses with median
JIS in the same range as the representative chronic
viruses EBV and CMV. We see that this broader set of
viruses also appear to have evolved sequences that con-
tained reduced T cell epitope content and increased
human cross-reactivity at the TCR facing residues of
T cell epitopes (stronger low-JIS tail in the distribution).
The striking outlier in this analysis is rubella, for
which a substantial fraction (50.8%) of fragments con-
tain no predicted binders and thus which cannot be
shown in the median-JIS plot. In order to better under-
stand why this virus exhibits this pattern, and how that
relates to some of the other representative viruses, the
overall amino acid content within the different genomes
was characterized. Figure 8 plots the log of the fraction
of some such genomes, relative to that of a background
set of proteins [31]. It also shows the corresponding
values for the pseudoepitopes used to establish the
empirical distribution for FTCR|MHC(e;a) as well as values
for human genome. As is well-known (and encapsulated
in epitope predictors), T cell epitopes are enriched in
hydrophobic residues (F, I, L, M, V); the plot shows that
in this dataset, the enrichment comes particularly at the
expense of negatively charged residues (D, E) as well as
a few others (C, G, P). The acute Marburg has similar
trends, while the chronic EBV is less consistent and
even reverses some of them. Human also reverses some
of the trends. Rubella goes against the trends to an
extreme degree, often in the same direction as human
and away from binders, but much further. Quantita-
tively, the Euclidean distance from the background fre-
quency distribution to the Rubella one is .117, while the
distance from background to EBV is .057, to Marburg
.058, to binders .067, and to human .037. Rubella is
even further away from the set of binders, at a distance
of .153; thus, Rubella has strikingly different amino acid
prevalence. While the implication of this finding is
uncertain, it may relate to an as-yet undescribed means
of immune escape. In future studies we plan to identify
pathogens that have similar amino acid distributions
and examine their relationship with human hosts.
Influenza proteins
For comparisons within virus species, JIS distributions
can be separately characterized for different proteins.
Using influenza as a case study, Figure 9 illustrates such
per-protein distributions for three different strains,
separating out the surface antigens HA and NA from
the others. As would be expected, in general HA and
NA are relatively de-immunized and somewhat shifted
toward lower JIS (which would reduce their overall abil-
ity to induce antibody responses). In contrast, NP and
NS1 have the biggest concentration of high-JIS epitopes,
while NEP’s broader JIS distribution suggests that it has
more human-like fragments than those. M2 is strikingly
de-immunized, a fact we attribute to a notably different
amino acid content supporting its structure and func-
tion as a proton channel, with specific patterns for for-
mation of a transmembrane homotetramer establishing
the pore, and a large number of E in the C terminus for
complex formation with M1 [35]).
In contrasting the different strains, H7N9 is generally
more deimmunized than H5N1 and H1N1, and is for
both HA and NA in particular. HA5 is also more deim-
munized than HA1. The low immunogenicity scores of
H7N9 has been previously reported by our group. The
significance of this finding is unknown, since neither
virus would have normally interacted with the human
immune system; this finding may be relevant to immune
responses that are directed against the virus by its other
hosts (birds and swine).
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Conclusions
While cross-reactivity is now understood as an intrinsic
characteristic of the T cell receptor, critical to training
and protection, this paper presents the first attempt to
quantitatively evaluate it, and to use such a characteriza-
tion in a genomic-scale study of how pathogens may use
this means of escaping an immune response. Our model
unifies into the novel Janus Immunogenicity Score both
sides of recognition: MHC-based epitope prediction and
extent of TCR-level cross-reactivity against self peptides
(conditioned on MHC binding). The predictive power of
the JIS is demonstrated by comparing epitopes in the
Figure 6 Median JIS over all 15mer fragments, treating predicted non-binders as the lowest JIS, for each of a set of different
human-host viruses. The medians of the representative viruses EBV, CMV, Marburg, Ebola are indicated at the bottom, along with the median
over all fragments in the plant-host virus set. The additional viruses are plotted at their median JIS, staggered in y value. Rubella is not shown, as
over 50% of its peptides are non-binders. The curve provides a kernel density estimation of the median JIS distribution.
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IEDB that are associated with T effector cytokines ("Teff-
pos”) vs. those that are associated with regulatory T cell
cytokine profiles or lack of immune response ("Teff-neg/
null”), and finding a statistically significant difference in
scores.
With this immunogenicity score in hand, we studied
profiles of viruses associated with chronic infection (hit-
and-stay) vs. those that cause acute disease and higher
mortality (hit-and-run), and found them to be significantly
different. Commensal viruses appear to avoid immune
Figure 7 JIS for viruses with low median JIS. Numbers in the legend correspond to the indices in Figure 6. (left) Percentage of fragments
predicted to be non-binders; (right) JIS distributions (kernel density estimation, truncated at -7) of predicted binders.
Figure 8 Relative amino acid content for selected viral genomes, a large set of random predicted epitopes, and the human genome.
The fraction of each amino acid type in each genome (or set of epitopes) is divided by the corresponding fraction in a background set of proteins.
The plot illustrates the log10 relative frequencies, so that overrepresented amino acids are and positive and underrepresented ones are negative.
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response by (1) reducing their epitope content and (2)
adopting more human-like TCR faces among the remaining
epitopes, when compared to acute viruses and plant-virus
controls. When expanding the analysis to a broader set of
viruses, several of these also appear to have evolved
sequences that contained reduced T cell epitope content
and increased human cross-reactivity at the TCR facing
residues of T cell epitopes (stronger low-JIS tail in the
Figure 9 JIS distributions over 15mer fragments in individual proteins in three influenza A strains. (left) Percentage of fragments
predicted to be non-binders; (middle, right) JIS distributions (kernel density estimation, truncated at -7) of predicted binders for common
proteins, with surface proteins separated from others.
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distribution). Rubella is a striking outlier, which may relate
to an as-yet undescribed means of immune escape. In
future studies we plan to identify pathogens that have simi-
lar amino acid distributions and examine their relationship
with human hosts.
And finally, among influenza viruses, H7N9 is gener-
ally more deimmunized than H5N1 and H1N1, and is
for both HA and NA in particular. HA5 is also more
deimmunized than HA1. The low immunogenicity
scores of H7N9 has been previously reported by our
group. The significance of this finding is unknown, since
neither virus would have normally interacted with the
human immune system; this finding may be relevant to
immune responses that are directed against the virus by
other hosts (birds and swine).
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